Literature DB >> 9225915

Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

D P Kelsen1, R Portenoy, H Thaler, Y Tao, M Brennan.   

Abstract

BACKGROUND: The purpose of our study was to evaluate the relationship between pain and resectability and survival in patients with operable pancreatic carcinoma.
METHODS: Pain, pain intensity, and pain location were prospectively assessed in newly diagnosed patients with operable adenocarcinoma of the pancreas. Patients were evaluated before their first operation at a large tertiary care cancer center. Pain factors were then correlated with outcomes of surgery, including resectability and survival.
RESULTS: Seventy-seven patients with operable pancreatic carcinoma were evaluated before operation. With the Memorial Pain Assessment Card and a demographic questionnaire, an analysis of analgesic use and pain prevalence and intensity were quantitated. Twenty-two (29%) of 77 patients reported no pain. Fifty-five had mild to severe pain. Moderately severe or greater pain (Memorial Pain Assessment Card Tursky scores of 5 or greater or visual analogue self-assessment pain intensity scores greater than 30) was found in 20 patients. Twenty-six (34%) patients had resectable disease. Of the 51 patients who did not have resections, 35 had metastatic disease. Locoregional unresectable disease without metastases was found in 16 patients. Resectability was correlated with the presence of pain (p = 0.04). The median survival for all patients was 6.7 months. Not surprisingly, patients undergoing resection had a significantly better median survival than did those whose disease was unresectable (5.5 versus 15.1 months). Pain before operation significantly predicted survival (median survival for those with pain, 5.7 months; for those without pain, 15 months; p = 0.003). Even among patients who underwent resection, the presence of pain was associated with a worse survival (21.9 months versus 9.2 months; p = 0.045). In a multivariate analysis the two significant variables were inability to undergo resection and presence of any pain.
CONCLUSIONS: The presence of pain in newly diagnosed patients with potentially operable pancreatic cancer is an ominous predictor of resectability and of survival. Even if the patient can undergo resection, the presence of preoperative pain is associated with a poor prognosis. Patients with operable pancreatic cancer who present with pain, even those whose evaluation shows a likelihood of resectability, are at high risk for recurrence with an impaired survival compared with those patients without pain.

Entities:  

Mesh:

Year:  1997        PMID: 9225915     DOI: 10.1016/s0039-6060(97)90264-6

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  49 in total

1.  [Chronic pancreatitis as a risk factor for the development of pancreatic cancer--diagnostic challenges].

Authors:  Tilman Pickartz; Julia Mayerle; Matthias Kraft; Matthias Evert; Katja Evert; Jens-Peter Kühn; Claus-Dieter Heidecke; Markus M Lerch
Journal:  Med Klin (Munich)       Date:  2010-04

2.  Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation.

Authors:  Douglas S Swords; Mary C Mone; Chong Zhang; Angela P Presson; Sean J Mulvihill; Courtney L Scaife
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

Review 3.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

Review 4.  Surgical palliation in patients with pancreatic cancer.

Authors:  Jörg Köninger; Moritz N Wente; Michael W Müller; Carsten N Gutt; Helmut Friess; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2006-11-11       Impact factor: 3.445

Review 5.  Celiac plexus block for visceral pain.

Authors:  Ian Carroll
Journal:  Curr Pain Headache Rep       Date:  2006-02

6.  A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer.

Authors:  Mona Kamal; Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Araceli Garcia-Gonzalez; Raza H Bokhari; Charles S Cleeland; David R Fogelman
Journal:  J Pain Symptom Manage       Date:  2020-01-24       Impact factor: 3.612

Review 7.  Investigation of abdominal pain to detect pancreatic cancer.

Authors:  J Ashley Guthrie; Maria B Sheridan
Journal:  BMJ       Date:  2008-05-10

Review 8.  Celiac plexus block and neurolysis for pancreatic cancer.

Authors:  Bret M Bahn; Michael A Erdek
Journal:  Curr Pain Headache Rep       Date:  2013-02

9.  Genome-wide association study of pancreatic cancer in Japanese population.

Authors:  Siew-Kee Low; Aya Kuchiba; Hitoshi Zembutsu; Akira Saito; Atsushi Takahashi; Michiaki Kubo; Yataro Daigo; Naoyuki Kamatani; Suenori Chiku; Hirohiko Totsuka; Sumiko Ohnami; Hiroshi Hirose; Kazuaki Shimada; Takuji Okusaka; Teruhiko Yoshida; Yusuke Nakamura; Hiromi Sakamoto
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

Review 10.  Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-01       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.